11
Participants
Start Date
June 30, 2016
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
Formulation A (ALS-008176)
Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.
Formulation B (ALS-008176)
60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.
Formulation C (ALS-008176)
60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.
Formulation D (ALS-008176)
60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.
Formulation E (ALS-008176)
60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.
Formulation F (ALS-008176)
60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.
Formulation G1 (ALS-008176)
60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
Formulation G2 (ALS-008176)
60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
Formulation G3 (ALS-008176)
60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
Formulation H1 (ALS-008176)
60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Formulation H2 (ALS-008176)
60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Formulation H3 (ALS-008176)
60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Nottingham
Janssen Research & Development, LLC
INDUSTRY